Cite
APA Citation
Korjian, S., Braunwald, E., Daaboul, Y., Verheugt, F., Bode, C., Tendera, M., Jain, P., Plotnikov, A., Burton, P., & Gibson, C. M. (2019). safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. European heart journal, 8(2), 186–193. http://access.bl.uk/ark:/81055/vdc_100078865222.0x000009